|

Busulfan Clinical Trials

22 actively recruiting trials across 11 locations

▲ +2 trials since May 2026

Also known as: 1, 4-Bis[methanesulfonoxy]butane, BUS, Bu, Busilvex, Bussulfam +27 more

Pipeline

Phase 1: 1Phase 2: 13Phase 3: 3Phase 1/2: 2Phase 2/3: 2

Top Sponsors

M.D. Anderson Cancer Center3
Fred Hutchinson Cancer Center3
St. Anna Kinderkrebsforschung2
National Cancer Institute (NCI)2
Nantes University Hospital2

Indications

Cancer22
Acute Myeloid Leukemia6
Myelodysplastic Syndrome5
Acute Lymphoblastic Leukemia5
Acute Leukemia4

Other6 trials

Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia

Phase 2/3

Allogeneic Stem Cell Transplantation in Relapsed/Refractory T-, NK/T-cell Lymphomas

Phase 2

High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN)

Phase 3

International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia

Phase 3

Study Comparing the Efficacy of 2 RIC Regimens (Clofarabine vs Fludarabine) in Adults With AML Eligible to Allo-SCT

Phase 2

Study Testing Two Conditioning Regimen With a Single Prophylaxis of GVHD by Cyclophosphamide and Methotrexate Post-transplant in Patients Eligible for Matched-donor Allograft Transplantation

Phase 2

New York, New York3 trials

Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders

Memorial Sloan Kettering Cancer Center

Phase 2

Cord Blood Transplantation in Children and Young Adults With Blood Cancer

Memorial Sloan Kettering Cancer Center (All Protocol Activities)

Phase 2

HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy

Memorial Sloan Kettering Cancer Center

Phase 2

Houston, Texas3 trials

Personalized NK Cell Therapy in CBT

M D Anderson Cancer Center

Phase 2

Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma

MD Anderson Cancer Center

Phase 2

Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS

M D Anderson Cancer Center

Phase 2/3

Birmingham, Alabama2 trials

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

University of Alabama at Birmingham Cancer Center

Phase 2

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

Children's Hospital of Alabama

Phase 3

Duarte, California1 trial

Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant

City of Hope Medical Center

Phase 1

Los Angeles, California1 trial

Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant

Children's Hospital of Los Angeles

Phase 2

Tampa, Florida1 trial

Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)

Moffitt Cancer Center

Phase 2

Bethesda, Maryland1 trial

Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies

National Institutes of Health Clinical Center

Phase 1/2

Minneapolis, Minnesota1 trial

MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies

University of Minnesota Masonic Cancer Center

Phase 2

St Louis, Missouri1 trial

Pilot Study of Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant in AML

Washington University School of Medicine

Phase 1/2

Rochester, New York1 trial

Umbilical Cord Blood Transplantation From Unrelated Donors

Wilmot Cancer Institute

Seattle, Washington1 trial

Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes

Fred Hutch/University of Washington Cancer Consortium

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.